<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bicuspid aortic valve: General management in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bicuspid aortic valve: General management in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bicuspid aortic valve: General management in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan C Braverman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Candice Silversides, MD, MS, FRCPC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 26, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3886124"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The bicuspid aortic valve condition is a valvulo-aortopathy (affecting both the aortic valve and the thoracic aorta) [<a href="#rid1">1</a>]. Adults with bicuspid aortic valves commonly develop aortic valve dysfunction and disease of the ascending aorta and therefore require surveillance and appropriate management of these conditions. The management of bicuspid aortic valve disease in adults includes surveillance, timely intervention for valve disease and aortopathy, treatment of hypertension, measures to address the risk of infective endocarditis, counseling patients on physical activity, and management prior to and during pregnancy. General noninterventional management for adults with bicuspid aortic valve will be discussed here.</p><p>Other aspects of management and diagnosis of bicuspid aortic valve in adults are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/129707.html" rel="external">"Bicuspid aortic valve: Intervention for valve disease or aortopathy in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1425.html" rel="external">"Bicuspid aortic valve: Management during pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8157.html" rel="external">"Clinical manifestations and diagnosis of bicuspid aortic valve in adults"</a>.)</p><p></p><p>Bicuspid aortic valve in children is discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5775.html" rel="external">"Valvar aortic stenosis in children"</a> and  <a class="medical medical_review" href="/z/d/html/5776.html" rel="external">"Subvalvar aortic stenosis (subaortic stenosis)"</a> and  <a class="medical medical_review" href="/z/d/html/5778.html" rel="external">"Aortic regurgitation in children"</a>.)</p><p></p><p class="headingAnchor" id="H1079320"><span class="h1">SURVEILLANCE</span><span class="headingEndMark"> — </span>To enable timely intervention, all patients with bicuspid aortic valves should be monitored for progressive aortic valve dysfunction (stenosis and/or regurgitation) as well as for thoracic aortic dilation given the risk of aneurysm formation and aortic dissection.</p><p class="headingAnchor" id="H2030307"><span class="h2">How frequently to monitor</span><span class="headingEndMark"> — </span>Echocardiography should be performed at intervals based upon the lesion requiring greatest frequency of surveillance among aortic stenosis, aortic regurgitation, and dilation of the aorta. Development of significant aortic stenosis is much more common than development of significant aortic regurgitation. The rate of aortic growth in bicuspid aortic valve patients is variable, ranging from 0.2 to 2.3 mm/year [<a href="#rid2">2-5</a>], depending upon patient characteristics [<a href="#rid6">6,7</a>]. Higher rates of growth are observed in older adults and those with larger aneurysms [<a href="#rid6">6,8,9</a>].</p><p>If the thoracic aorta cannot be adequately assessed by echocardiography, these are assessed by magnetic resonance imaging (MRI) or computed tomography (CT), as described below. (See <a class="local">'How to monitor'</a> below.)</p><p>The following recommendations for surveillance and management for aortic stenosis, aortic regurgitation, and aortic dilation are in broad agreement with the 2022 American College of Cardiology/American Heart Association (ACC/AHA) guideline for the diagnosis and management of aortic disease, the 2020 ACC/AHA valve guidelines, the 2018 ACC/AHA adult congenital heart disease guidelines, the 2015 ACC/AHA scientific statement on eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities, and the 2018 American Association for Thoracic Surgery bicuspid aortic valve-related aortopathy guidelines [<a href="#rid10">10-14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For adults with aortic stenosis:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>With severe aortic stenosis (defined as peak jet velocity ≥4 m/sec, mean gradient &gt;40 mmHg, or valve area &lt;1.0 cm<sup>2</sup>), we suggest Doppler echocardiography every 6 to 12 months.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>With moderate aortic stenosis (defined as peak jet velocity 3 to 3.9 m/sec, mean gradient 25 to 40 mmHg, or valve area 1.0 to 1.5 cm<sup>2</sup>), we suggest Doppler echocardiography every one to two years.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>With mild aortic stenosis (defined as peak jet velocity 2.0 to 2.9 m/sec, mean gradient &lt;25 mmHg, or valve area &gt;1.5 cm<sup>2</sup>), we suggest Doppler echocardiography every three to five years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For adults with aortic regurgitation:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>With severe aortic regurgitation, we suggest Doppler echocardiography every 6 to 12 months (more frequently if the left ventricle is dilating).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>With moderate aortic regurgitation, we suggest Doppler echocardiography every one to two years.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>With mild aortic regurgitation, we suggest Doppler echocardiography every three to five years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For adults with bicuspid aortic valve, serial evaluation of the size and morphology of the aortic sinuses and ascending aorta by echocardiography (generally transthoracic echocardiography [TTE]), MRI, or CT) is recommended, with the examination interval determined by the aortic size, the rate of progression of aortic dilation, and other risk factors, including family history [<a href="#rid13">13-15</a>]. When the aortic diameter is approaching a surgical threshold, more frequent imaging is reasonable.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If thoracic aortic diameters are normal, the thoracic aorta should be reassessed every three to five years [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the aortic root or tubular ascending aorta measures 4.0 to 4.9 cm, the thoracic aorta should be reimaged at 12 months. After this initial reimaging, if the aortic root or tubular ascending aorta measures 4.0 to 4.4 cm and remains stable, then surveillance imaging is continued every two or three years. If the aortic diameter is 4.5 to 4.9 cm and remains stable, then annual imaging is recommended.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the aortic root or ascending aorta diameter is 5.0 to 5.4 cm or if there is a rapid rate of change in aortic diameter (ie, &gt;3 mm/year), then reassessment of the aortic root and ascending aorta size should be performed more frequently [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/129707.html" rel="external">"Bicuspid aortic valve: Intervention for valve disease or aortopathy in adults", section on 'Approach to identifying candidates for aortic surgery'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For competitive athletes with bicuspid aortic valve and aortic dilation &gt;40 mm, annual monitoring of the aorta with echocardiography or cardiovascular magnetic resonance (CMR) imaging is recommended [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a patient requires cardiac surgery (eg, for aortic valve dysfunction) and has an aortic root or ascending aortic measurement of 40 to 44 mm on TTE, preoperative assessment of the thoracic aorta by CMR or CT is recommended to determine if concomitant aortic surgery is indicated [<a href="#rid15">15</a>].</p><p></p><p>Earlier reevaluation (beyond the surveillance regimen described above) is indicated for changes in symptoms or examination and for hemodynamic assessment related to pregnancy (see  <a class="medical medical_review" href="/z/d/html/1425.html" rel="external">"Bicuspid aortic valve: Management during pregnancy"</a>). Of note, although surveillance of the aorta is based upon aortic diameter, other factors (eg, genetic factors, hemodynamic effects) likely contribute to the risk of acute aortic events (eg, aortic dissection and aortic rupture) [<a href="#rid6">6</a>].</p><p>As discussed separately, first-degree relatives of patients with bicuspid aortic valve should be evaluated for the presence of bicuspid aortic valve and thoracic aortic disease. (See  <a class="medical medical_review" href="/z/d/html/8157.html" rel="external">"Clinical manifestations and diagnosis of bicuspid aortic valve in adults", section on 'Screening'</a>.)</p><p class="headingAnchor" id="H2030313"><span class="h2">How to monitor</span><span class="headingEndMark"> — </span>Aortic valve disease surveillance is performed by clinical assessment (of symptoms and signs) and imaging of the ascending aorta and aortic arch. The maximum end-diastolic diameter perpendicular to aortic flow is measured in mm for each segment along the thoracic aorta including the aortic root (sinus to sinus or sinus to commissure), sinotubular junction, ascending aorta, aortic arch, and descending thoracic aorta [<a href="#rid14">14-16</a>].</p><p>As discussed separately, evaluation for coarctation of the aorta is also warranted; if coarctation is detected, screening for cerebral aneurysms is indicated. (See  <a class="medical medical_review" href="/z/d/html/8157.html" rel="external">"Clinical manifestations and diagnosis of bicuspid aortic valve in adults", section on 'Coarctation of the aorta'</a>.)</p><p class="headingAnchor" id="H1437783538"><span class="h3">Imaging modalities</span><span class="headingEndMark"> — </span>TTE is used for monitoring the thoracic aorta if image quality is adequate. There are many different phenotypes of aortic enlargement with bicuspid aortic valve (bicuspid valve "aortopathy") [<a href="#rid1">1,17</a>]. The most common site of aortic dilation is at the ascending aorta, and monitoring by transthoracic echocardiography is often inadequate at this level unless high right parasternal views are obtained. (See  <a class="medical medical_review" href="/z/d/html/8157.html" rel="external">"Clinical manifestations and diagnosis of bicuspid aortic valve in adults", section on 'Aortic dilation and aortic dissection'</a> and  <a class="medical medical_review" href="/z/d/html/5293.html" rel="external">"Echocardiographic evaluation of the thoracic and proximal abdominal aorta"</a>.)</p><p>If any segment of the thoracic aorta is not adequately visualized by TTE, any segment measures ≥45 mm, or aortic coarctation cannot be ruled out, then the entire thoracic aorta should be imaged by CMR (with no contrast generally required) or CT (both electrocardiogram [ECG]-gated) [<a href="#rid14">14,15</a>]. If TTE measurements are consistent with CMR or CT measurements, then interval aortic measurement may be performed by TTE with repeat CMR or CT every three years to reconfirm agreement [<a href="#rid15">15</a>]. If TTE and CMR or CT measurements are discordant, then CMR or CT should be used for interval aortic measurements. In the interest of reducing radiation exposure, for adults &lt;50 years old, CMR is preferred if feasible.</p><p>The maximum diameter of an asymmetric aortic root at the sinuses of Valsalva is commonly underestimated in the TTE parasternal long-axis view, so it is important to measure this diameter also in the parasternal short-axis view or to proceed directly to CMR or CT imaging if root dilation is suspected [<a href="#rid15">15,16</a>].</p><p class="headingAnchor" id="H1167982715"><span class="h3">How to measure</span><span class="headingEndMark"> — </span>Measurement conventions differ among imaging modalities:</p><p>On echocardiographic images, a leading-edge to leading-edge measurement is used, since normative echocardiography data for the aortic root (except for the aortic annulus) were developed using the leading-edge to leading-edge technique [<a href="#rid14">14-16,18</a>]. However, the aortic annulus at the hinge points of the aortic valve leaflets is measured using the inner edge to inner edge [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/5293.html" rel="external">"Echocardiographic evaluation of the thoracic and proximal abdominal aorta"</a>.)</p><p>On CMR or contrast CT images, we favor using the external (outer to outer) diameter. It is important to ensure that a consistent measurement technique is used, particularly given the lack of consensus on whether to use the external or internal diameters for CMR and CT images [<a href="#rid15">15,16</a>]. In patients requiring serial imaging, CMR is preferred to avoid repeated radiation exposure. Determination of aorta size by CMR generally does not require exogeneous gadolinium contrast agent administration. In patients with impaired renal function, the risk of iodinated intravenous contrast for contrast CT and the risk of gadolinium contrast should be considered.</p><p class="headingAnchor" id="H2923667545"><span class="h3">Comparison</span><span class="headingEndMark"> — </span>After aortic measurements are made, comparison is made with normal reference values as well as prior studies (most recent as well as earliest) using the same imaging modality by a clinician with expertise in that imaging technique [<a href="#rid14">14-16</a>]. Some experts use nomograms to assess how an individual's aortic dimensions compare with those in normal subjects with the same age and body size  (<a class="graphic graphic_figure graphicRef97883" href="/z/d/graphic/97883.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef97882" href="/z/d/graphic/97882.html" rel="external">figure 2</a>). When identifying rapid aortic growth (ie, &gt;3 mm/year), it is important to document aortic size on repeated measurements using the same imaging technique at the same aortic level with side-by-side comparison by a clinician with expertise in that imaging modality [<a href="#rid14">14,15,19,20</a>]. Comparison with the earliest prior image is important to detect gradual growth that can be may be missed when comparing only recent images [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H3239420267"><span class="h1">INTERVENTION</span><span class="headingEndMark"> — </span>Indications for intervention for aortic valve disease (stenosis or regurgitation) and for aortopathy associated with bicuspid aortic valve are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/129707.html" rel="external">"Bicuspid aortic valve: Intervention for valve disease or aortopathy in adults"</a>.)</p><p class="headingAnchor" id="H3886138"><span class="h1">PHARMACOLOGIC THERAPY</span><span class="headingEndMark"> — </span>The role of drug therapy in patients with bicuspid aortic valve is limited, as evidence of efficacy is lacking [<a href="#rid12">12,13,19</a>]. No drug has been found to alter the natural history of bicuspid aortic valve disease or aortic stenosis more generally. (See  <a class="medical medical_review" href="/z/d/html/8117.html" rel="external">"Medical management of asymptomatic aortic stenosis in adults", section on 'Prevention of disease progression'</a>.)</p><p>While no drug has been shown to improve outcomes in patients with bicuspid aortic valve (including those with dilated aortic roots and/or aortic valve disease), hypertension, when present, should be treated according to standard guidelines [<a href="#rid12">12,13,19</a>]. (See  <a class="medical medical_review" href="/z/d/html/3852.html" rel="external">"Overview of hypertension in adults"</a>.)</p><p>For patients with bicuspid aortic valve, chronic aortic regurgitation, and systemic hypertension (systolic blood pressure &gt;140 mmHg), vasodilator therapy (such as angiotensin converting enzyme inhibitors, angiotensin II receptor blockers [ARBs], or dihydropyridine calcium channel blockers) are favored since they may reduce systolic blood pressure in this setting. Beta blocker therapy may be less effective in the setting of severe aortic regurgitation since reduction in heart rate and the associated increase in stroke volume may contribute to elevated systolic pressure and may contribute to an increase in regurgitant volume. (See  <a class="medical medical_review" href="/z/d/html/8160.html" rel="external">"Natural history and management of chronic aortic regurgitation in adults", section on 'Pharmacologic therapy'</a>.)</p><p>For patients with bicuspid aortic valve and dilated aortic root or ascending aorta without hypertension, there are no pharmacologic therapies proven to lessen aortic dilation or lessen the risk of aortic dissection or rupture. Some clinicians use beta blockers in this setting based upon the theoretical benefit and likely minimal risk. Beta blockers have a conceptual advantage in reducing the aortic wall stress which might reduce the rate of progression, but there are no outcomes data in this population to provide guidance [<a href="#rid13">13</a>]. The 2022 American College of Cardiology/American Heart Association (ACC/AHA) guideline for the diagnosis and management of aortic disease [<a href="#rid14">14</a>] and the 2020 ACC/AHA valve guidelines do not recommend any pharmacologic treatment in the absence of another indication, such as hypertension [<a href="#rid13">13</a>]. By contrast, the 2017 European Society of Cardiology guideline notes that use of beta blocker or <a class="drug drug_general" data-topicid="9574" href="/z/d/drug information/9574.html" rel="external">losartan</a> in patients with bicuspid aortic valve and aortic root and/or ascending aorta dilation is common clinical practice, although evidence to support this approach is lacking [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/8189.html" rel="external">"Management of thoracic aortic aneurysm in adults", section on 'Antihypertensive therapies'</a>.)</p><p>While some studies have found alterations in transforming growth factor-beta (TGF-beta) signaling in the aortas of patients with bicuspid aortic valve [<a href="#rid22">22,23</a>], evidence is lacking as to whether pharmacologic therapy directed against this signaling pathway (such as ARB drugs) can alter the risk of aortic aneurysm in patients with bicuspid aortic valve disease.</p><p>Since fluroquinolones have been linked to an increased risk of aortic dissection and aneurysm rupture, it is recommended that these drugs be avoided when possible in patients with bicuspid aortic valve and aortic aneurysm. As noted in US Food and Drug Administration labeling for these drugs, in patients with known aortic aneurysm or at increased risk for aortic aneurysm, fluoroquinolone use is reserved only for settings in which no alternative antibacterial treatment is available [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/z/d/html/8189.html" rel="external">"Management of thoracic aortic aneurysm in adults", section on 'Avoidance of fluoroquinolones'</a>.)</p><p class="headingAnchor" id="H595814632"><span class="h1">ENDOCARDITIS PREVENTION</span><span class="headingEndMark"> — </span>Although the patient with bicuspid aortic valve is at risk for endocarditis, antibiotic prophylaxis is not recommended for isolated bicuspid aortic valve [<a href="#rid13">13,25-27</a>]. Individuals with bicuspid aortic valve should receive education about the risk of endocarditis and means of reducing the risk, including good dental care and oral health practices, awareness of symptoms of infection (including symptoms suggesting endocarditis, such as unexplained fevers, chills, and night sweats), and the importance of prompt reporting of symptoms of concern to health care providers. (See  <a class="medical medical_review" href="/z/d/html/2147.html" rel="external">"Prevention of endocarditis: Antibiotic prophylaxis and other measures"</a> and  <a class="medical medical_review" href="/z/d/html/8157.html" rel="external">"Clinical manifestations and diagnosis of bicuspid aortic valve in adults", section on 'Infective endocarditis'</a>.)</p><p>Individuals with bicuspid aortic valves are at increased risk of infective endocarditis compared with the general population and have a higher incidence of perivalvular abscess compared with those with tricuspid aortic valves [<a href="#rid17">17,28</a>]. In a community cohort from Olmstead county, the incidence of infective endocarditis (definite and possible) in individuals with a bicuspid aortic valve was estimated to be 10 per 10,000 patient-years, resulting in an age-adjusted relative risk of endocarditis for those with bicuspid aortic valve of 17 compared with that of the general population [<a href="#rid29">29</a>]. A meta-analysis of eight longitudinal cohort studies of infective endocarditis incidence included 5351 individuals with a bicuspid aortic valve [<a href="#rid30">30</a>]. During follow-up, 184 patients with bicuspid aortic valve developed infective endocarditis, with an incidence of 48 per 10,000 patient years (95% CI 22-74) and a 12-fold (95% CI 5-27) increased risk compared with the general population. The reported lifetime incidence of infective endocarditis in individuals with bicuspid aortic valve is 2 to 5 percent [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H3886145"><span class="h1">PHYSICAL ACTIVITY AND EXERCISE</span><span class="headingEndMark"> — </span>Recommendations about exercise and physical activity for individuals with a bicuspid aortic valve are tailored to the type and severity of valve disease present (aortic stenosis or aortic regurgitation) and the presence of a dilated aortic root or ascending aorta. Guidelines for physical activity in patients with aortic stenosis and aortic regurgitation are discussed separately [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/8117.html" rel="external">"Medical management of asymptomatic aortic stenosis in adults", section on 'Physical activity and exercise'</a> and  <a class="medical medical_review" href="/z/d/html/8160.html" rel="external">"Natural history and management of chronic aortic regurgitation in adults", section on 'Recommendations for physical activity and exercise'</a>.)</p><p>Because certain physical activities lead to increases in blood pressure and aortic wall stress, lifestyle modification is necessary when significant aortic dilation is associated with bicuspid aortic valve disease. The 2015 American Heart Association/American College of Cardiology guidelines for competitive athletes with cardiovascular abnormalities provide exercise and sports participation recommendations for athletes with bicuspid aortic valve and aortic dilation [<a href="#rid11">11</a>]. These statements are starting points for the discussion of participation in various sports for the competitive athlete with a bicuspid aortic valve  (<a class="graphic graphic_figure graphicRef105651" href="/z/d/graphic/105651.html" rel="external">figure 3</a> and <a class="graphic graphic_table graphicRef105803" href="/z/d/graphic/105803.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Athletes with bicuspid aortic valve can participate in all competitive athletics if the aortic root and ascending aorta are not dilated (ie, z-score &lt;2, &lt;2 standard deviations from the mean, or &lt;40 mm). The function of the bicuspid aortic valve (whether stenotic or regurgitant) is also important in determining participation recommendations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adult athletes with a bicuspid aortic valve and a mild to moderately dilated aorta (z-score 2 to 3.5, or aortic root or ascending aortic diameters measuring 40 to 42 mm in men or 36 to 39 mm in women) and no features of associated connective tissue disorder or familial thoracic aortic aneurysm syndrome may participate in low and moderate static and dynamic competitive sports (classes IA, IB, IC, IIA, IIB, and IIC) with a low likelihood of significant bodily collision  (<a class="graphic graphic_figure graphicRef105651" href="/z/d/graphic/105651.html" rel="external">figure 3</a> and <a class="graphic graphic_table graphicRef105803" href="/z/d/graphic/105803.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adult competitive athletes with bicuspid aortic valve and a severely dilated aorta (z-score &gt;3.5 to 4, or &gt;43 mm in men or &gt;40 mm in women) should not participate in any competitive sports that involve the potential for bodily collision  (<a class="graphic graphic_table graphicRef105803" href="/z/d/graphic/105803.html" rel="external">table 1</a>). Athletes with a bicuspid aortic valve and a dilated aorta measuring 43 to 45 mm may participate in low-intensity competitive sports (class IA) with a low likelihood of bodily collision  (<a class="graphic graphic_figure graphicRef105651" href="/z/d/graphic/105651.html" rel="external">figure 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Athletes with bicuspid aortic valve and a markedly dilated aorta (&gt;45 mm) should not participate in any competitive sports.</p><p></p><p>In practical terms, many adolescents and young adults with bicuspid aortic valves have mildly dilated aortas (ie, z-score &gt;2 to 3), yet the absolute aortic diameter remains in a range (ie, 4.0 to 4.5 cm) that is associated with a low risk of acute aortic dissection. In these cases, after an informed and shared decision-making discussion, many experts agree to allow continued participation in competitive sports with serial imaging follow-up of aortic dimensions. In these instances, it is important to exclude cases of underlying genetic aortopathy (ie, those associated with familial or heritable aneurysm disease) and Turner syndrome, since these conditions have higher risks of aortic complications. Avoidance of intense weight training is recommended for athletes with significant aortic dilation who choose to continue to participate in competitive sports.</p><p class="headingAnchor" id="H2484808879"><span class="h1">NONCARDIAC SURGERY</span><span class="headingEndMark"> — </span>Patients with bicuspid aortic valve may require noncardiac surgery. The risks of surgery depend largely upon the severity of associated aortic stenosis or aortic regurgitation, as well as any accompanying ascending aortic disease. The management of the patient with aortic stenosis or aortic regurgitation undergoing noncardiac surgery is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8124.html" rel="external">"Noncardiac surgery in adults with aortic stenosis"</a> and  <a class="medical medical_review" href="/z/d/html/8131.html" rel="external">"Noncardiac surgery in patients with mitral or aortic regurgitation", section on 'Chronic aortic regurgitation'</a>.)</p><p class="headingAnchor" id="H3886152"><span class="h1">PREGNANCY</span><span class="headingEndMark"> — </span>Preconception evaluation and counseling, and management of bicuspid aortic valve disease and aortopathy during pregnancy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1425.html" rel="external">"Bicuspid aortic valve: Management during pregnancy"</a>.)</p><p class="headingAnchor" id="H2106684922"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/129633.html" rel="external">"Society guideline links: Bicuspid aortic valve"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/115482.html" rel="external">"Society guideline links: Cardiac valve disease"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/118034.html" rel="external">"Society guideline links: Aortic dissection and other acute aortic syndromes"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/122280.html" rel="external">"Society guideline links: Congenital heart disease in adults"</a>.)</p><p class="headingAnchor" id="H3886201"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General management</strong> – The management of bicuspid aortic valve disease in adults includes surveillance, intervention for aortic valve disease and aortopathy, treatment of hypertension, measures to address the risk of infective endocarditis, counseling patients on physical activity, management of risk if noncardiac surgery is required, and counseling and management prior to and during pregnancy. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – To enable timely intervention, all patients with bicuspid aortic valves should be monitored for progressive aortic valve dysfunction (stenosis and/or regurgitation) as well as for thoracic aortic dilation given the risk of aneurysm formation and aortic dissection. Serial evaluation of the size and morphology of the aortic sinuses and ascending aorta is recommended, with the examination interval determined by the aortic size, the rate of progression of aortic dilation, and other risk factors, including family history. When the aortic diameter approaches a surgical threshold, more frequent imaging is reasonable. (See <a class="local">'How frequently to monitor'</a> above.)</p><p></p><p class="bulletIndent1">Transthoracic echocardiography (TTE) is used for monitoring the thoracic aorta if image quality is adequate. If any segment of the thoracic aorta is not adequately visualized by TTE, any segment measures ≥45 mm, or aortic coarctation cannot be ruled out, then the entire thoracic aorta should be imaged by ECG-gated magnetic resonance imaging or ECG-gated computed tomography. (See <a class="local">'How to monitor'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limited role of drug therapy</strong> – The role of pharmacologic therapy for patients with bicuspid aortic valve disease is limited, as no drug has been shown to improve outcomes in patients with bicuspid aortic valve. (See <a class="local">'Pharmacologic therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For hypertension</strong> – If hypertension is present, it should be treated according to standard guidelines. (See  <a class="medical medical_review" href="/z/d/html/3852.html" rel="external">"Overview of hypertension in adults"</a>.)</p><p></p><p class="bulletIndent2">For patients with bicuspid aortic valve, chronic aortic regurgitation, and systemic hypertension (systolic blood pressure &gt;140 mmHg), vasodilators (such as angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, or dihydropyridine calcium channel blockers) are favored since they may reduce systolic blood pressure in this setting. Beta blocker therapy may be less effective in this setting. (See  <a class="medical medical_review" href="/z/d/html/8160.html" rel="external">"Natural history and management of chronic aortic regurgitation in adults", section on 'Pharmacologic therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Without hypertension</strong> – For patients with bicuspid aortic valve and dilated aortic root or ascending aorta without hypertension, there are no pharmacologic therapies proven to lessen aortic dilation or lessen the risk of aortic dissection or rupture. Some clinicians use beta blockers in this setting based upon theoretical benefit and likely minimal risk. (See  <a class="medical medical_review" href="/z/d/html/8189.html" rel="external">"Management of thoracic aortic aneurysm in adults", section on 'Antihypertensive therapies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endocarditis</strong> – Individuals with bicuspid aortic valve should receive education about the risk of endocarditis and means of reducing the risk, including good dental care and oral health practices, awareness of symptoms of infection (including symptoms suggesting endocarditis, such as unexplained fevers, chills, and night sweats), and the importance of prompt reporting of symptoms of concern to health care providers. (See  <a class="medical medical_review" href="/z/d/html/8157.html" rel="external">"Clinical manifestations and diagnosis of bicuspid aortic valve in adults", section on 'Infective endocarditis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exercise</strong> – Recommendations about exercise and physical activity for individuals with a bicuspid aortic valve are tailored to the type and severity of valve disease present (aortic stenosis or aortic regurgitation) and the presence of a dilated aortic root or ascending aorta. (See <a class="local">'Physical activity and exercise'</a> above.)</p><p></p><p class="headingAnchor" id="H16752455"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Martin G Keane, MD, FACC, FAHA, FASE, Thomas P Graham, MD, and Catherine M Otto, MD, who contributed to earlier versions of this topic review.</p><p>The UpToDate editorial staff also acknowledges Martin St. John Sutton, MD (deceased), who contributed to earlier versions of this topic.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Michelena HI, Della Corte A, Evangelista A, et al. International consensus statement on nomenclature and classification of the congenital bicuspid aortic valve and its aortopathy, for clinical, surgical, interventional and research purposes. J Thorac Cardiovasc Surg 2021; 162:e383.</a></li><li><a class="nounderline abstract_t">Verma S, Siu SC. Aortic dilatation in patients with bicuspid aortic valve. N Engl J Med 2014; 370:1920.</a></li><li><a class="nounderline abstract_t">Avadhani SA, Martin-Doyle W, Shaikh AY, Pape LA. Predictors of ascending aortic dilation in bicuspid aortic valve disease: a five-year prospective study. Am J Med 2015; 128:647.</a></li><li><a class="nounderline abstract_t">Detaint D, Michelena HI, Nkomo VT, et al. Aortic dilatation patterns and rates in adults with bicuspid aortic valves: a comparative study with Marfan syndrome and degenerative aortopathy. Heart 2014; 100:126.</a></li><li><a class="nounderline abstract_t">Della Corte A, Bancone C, Buonocore M, et al. Pattern of ascending aortic dimensions predicts the growth rate of the aorta in patients with bicuspid aortic valve. JACC Cardiovasc Imaging 2013; 6:1301.</a></li><li><a class="nounderline abstract_t">Hardikar AA, Marwick TH. Surgical thresholds for bicuspid aortic valve associated aortopathy. JACC Cardiovasc Imaging 2013; 6:1311.</a></li><li class="breakAll">Braverman AC. The bicuspid aortic valve and associated aortic disease. In: Valvular Heart Disease, 4th Ed, Otto CM, Bonow RO (Eds), Saunders/Elsevier, Philadelphia 2013. p.179.</li><li><a class="nounderline abstract_t">Davies RR, Kaple RK, Mandapati D, et al. Natural history of ascending aortic aneurysms in the setting of an unreplaced bicuspid aortic valve. Ann Thorac Surg 2007; 83:1338.</a></li><li><a class="nounderline abstract_t">Zafar MA, Wu J, Vinholo TF, et al. Bicuspid aortopathy does not require earlier surgical intervention. J Thorac Cardiovasc Surg 2023.</a></li><li><a class="nounderline abstract_t">Bonow RO, Nishimura RA, Thompson PD, Udelson JE. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 5: Valvular Heart Disease: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol 2015; 66:2385.</a></li><li><a class="nounderline abstract_t">Braverman AC, Harris KM, Kovacs RJ, Maron BJ. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 7: Aortic Diseases, Including Marfan Syndrome: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol 2015; 66:2398.</a></li><li><a class="nounderline abstract_t">Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73:e81.</a></li><li><a class="nounderline abstract_t">Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021; 143:e72.</a></li><li><a class="nounderline abstract_t">Isselbacher EM, Preventza O, Hamilton Black J 3rd, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 2022; 146:e334.</a></li><li><a class="nounderline abstract_t">Borger MA, Fedak PWM, Stephens EH, et al. The American Association for Thoracic Surgery consensus guidelines on bicuspid aortic valve-related aortopathy: Full online-only version. J Thorac Cardiovasc Surg 2018; 156:e41.</a></li><li><a class="nounderline abstract_t">Evangelista A, Sitges M, Jondeau G, et al. Multimodality imaging in thoracic aortic diseases: a clinical consensus statement from the European Association of Cardiovascular Imaging and the European Society of Cardiology working group on aorta and peripheral vascular diseases. Eur Heart J Cardiovasc Imaging 2023; 24:e65.</a></li><li class="breakAll">Braverman AC, Cheng A. The bicuspid aortic valve and associated aortic disease. In: Valvular Heart Disease, 5th ed, Otto CM, Bonow RO (Eds), Elsevier 2021. p.197.</li><li><a class="nounderline abstract_t">Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28:1.</a></li><li><a class="nounderline abstract_t">Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 2010; 121:e266.</a></li><li><a class="nounderline abstract_t">Adamo L, Braverman AC. Surgical threshold for bicuspid aortic valve aneurysm: a case for individual decision-making. Heart 2015; 101:1361.</a></li><li><a class="nounderline abstract_t">Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38:2739.</a></li><li><a class="nounderline abstract_t">Gomez D, Al Haj Zen A, Borges LF, et al. Syndromic and non-syndromic aneurysms of the human ascending aorta share activation of the Smad2 pathway. J Pathol 2009; 218:131.</a></li><li><a class="nounderline abstract_t">Forte A, Della Corte A, Grossi M, et al. Early cell changes and TGFβ pathway alterations in the aortopathy associated with bicuspid aortic valve stenosis. Clin Sci (Lond) 2013; 124:97.</a></li><li class="breakAll">https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics (Accessed on November 05, 2020).</li><li><a class="nounderline abstract_t">Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33:2451.</a></li><li><a class="nounderline abstract_t">Michelena HI, Prakash SK, Della Corte A, et al. Bicuspid aortic valve: identifying knowledge gaps and rising to the challenge from the International Bicuspid Aortic Valve Consortium (BAVCon). Circulation 2014; 129:2691.</a></li><li><a class="nounderline abstract_t">Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116:1736.</a></li><li><a class="nounderline abstract_t">Zegri-Reiriz I, de Alarcón A, Muñoz P, et al. Infective Endocarditis in Patients With Bicuspid Aortic Valve or Mitral Valve Prolapse. J Am Coll Cardiol 2018; 71:2731.</a></li><li><a class="nounderline abstract_t">Michelena HI, Katan O, Suri RM, et al. Incidence of Infective Endocarditis in Patients With Bicuspid Aortic Valves in the Community. Mayo Clin Proc 2016; 91:122.</a></li><li><a class="nounderline abstract_t">Pereira SC, Abrantes AL, António PS, et al. Infective endocarditis risk in patients with bicuspid aortic valve: Systematic review and meta-analysis. Int J Cardiol Heart Vasc 2023; 47:101249.</a></li><li class="breakAll">Braverman AC, Cheng A. The bicuspid valve and associated aortic disease. In: Valvular Heart Disease, 5th ed, Otto CM, Bonow RO (Eds), Saunders/Elsevier, Philadelphia 2018.</li></ol></div><div id="topicVersionRevision">Topic 8155 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34304896" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : International consensus statement on nomenclature and classification of the congenital bicuspid aortic valve and its aortopathy, for clinical, surgical, interventional and research purposes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24827036" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Aortic dilatation in patients with bicuspid aortic valve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25644322" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Predictors of ascending aortic dilation in bicuspid aortic valve disease: a five-year prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24254191" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Aortic dilatation patterns and rates in adults with bicuspid aortic valves: a comparative study with Marfan syndrome and degenerative aortopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24269260" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pattern of ascending aortic dimensions predicts the growth rate of the aorta in patients with bicuspid aortic valve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24332283" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Surgical thresholds for bicuspid aortic valve associated aortopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24332283" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Surgical thresholds for bicuspid aortic valve associated aortopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17383337" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Natural history of ascending aortic aneurysms in the setting of an unreplaced bicuspid aortic valve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37088130" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Bicuspid aortopathy does not require earlier surgical intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26542667" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 5: Valvular Heart Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26542664" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 7: Aortic Diseases, Including Marfan Syndrome: A Scientific Statement From the American Heart Association and American College of Cardiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30121239" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33332150" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36322642" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30011777" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The American Association for Thoracic Surgery consensus guidelines on bicuspid aortic valve-related aortopathy: Full online-only version.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36881779" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Multimodality imaging in thoracic aortic diseases: a clinical consensus statement from the European Association of Cardiovascular Imaging and the European Society of Cardiology working group on aorta and peripheral vascular diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36881779" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Multimodality imaging in thoracic aortic diseases: a clinical consensus statement from the European Association of Cardiovascular Imaging and the European Society of Cardiology working group on aorta and peripheral vascular diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25559473" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20233780" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26076937" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Surgical threshold for bicuspid aortic valve aneurysm: a case for individual decision-making.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28886619" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : 2017 ESC/EACTS Guidelines for the management of valvular heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19224541" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Syndromic and non-syndromic aneurysms of the human ascending aorta share activation of the Smad2 pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22857993" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Early cell changes and TGFβpathway alterations in the aortopathy associated with bicuspid aortic valve stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22857993" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Early cell changes and TGFβpathway alterations in the aortopathy associated with bicuspid aortic valve stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22922415" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Guidelines on the management of valvular heart disease (version 2012).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24958752" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Bicuspid aortic valve: identifying knowledge gaps and rising to the challenge from the International Bicuspid Aortic Valve Consortium (BAVCon).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17446442" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29903346" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Infective Endocarditis in Patients With Bicuspid Aortic Valve or Mitral Valve Prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26763517" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Incidence of Infective Endocarditis in Patients With Bicuspid Aortic Valves in the Community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37547264" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Infective endocarditis risk in patients with bicuspid aortic valve: Systematic review and meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
